Sector News

Kiss more pharma jobs goodbye: Pierre Fabre to cut 550 in sales, R&D

December 11, 2014
Life sciences
Pierre Fabre hasn’t had an easy time in the drug business lately. Its R&D operations have been less than productive, executives say, and sales in its home country have suffered from price cuts.
 
So, it’s scaling back in pharma to narrow its R&D focus, build up in consumer healthcare and spend more resources on its cosmetics and dermatology businesses. The upshot? Pierre Fabre will shrink its pharma payroll by 551 jobs by 2016. The cuts will mainly affect its French operations, with sales and R&D both in the target zone.
 
The larger cuts will come in R&D, which will lose 272 jobs, 255 in France, the company said in a statement. Another 279 or so will hit on the sales side. The rest will come from an R&D site in Barcelona that’s slated for closure.
 
The job cuts aren’t likely to be popular in France, where Sanofi ran into trouble with its own restructuring. Nor are the company’s comments about its R&D operations in the country, which it called “insufficiently productive.” That, too, echoes Sanofi, whose now-former CEO Chris Viehbacher cited the same reason for his French job-cutting plans in R&D.
 
Pierre Fabre is far from the only drugmaker cutting jobs and paring away lackluster businesses–not to mention scaling back in France. Novartis just cut 200 people from its New Jersey payroll in a sales-force shift, and it’s cutting other jobs around the world as it consolidates back-office operations. The Swiss drugmaker is also in the midst of a wholesale strategic shift, selling its animal health business to Eli Lilly and swapping its vaccine business to GlaxoSmithKline for GSK’s oncology operations. GSK announced job cuts last week as well.
 
Bristol-Myers Squibb also said last week it would hack 1,000 from its Chinese payroll. And Merck is cutting costs–as well as jobs–as it narrows its focus; the U.S.-based drugmaker recently sold its consumer business to Bayer.
 
By Tracy Staton
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”